# of Displayed Technologies: 9 / 9

Applied Category Filter (Click To Remove): Oncology


Categories

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Kudryashova, Elena
  • Licensing Officer: Flammang, Ann Marie

Multifunctional RNA Nanoparticles and Methods for Treating Cancer
TS-040289 — Three-way junction nanoparticles for delivery of tamoxifen and other therapeutics directly to tumor cells.
Most breast cancers express estrogen receptor alpha (ER α) and antagonists of ER α drugs, such as tamoxifen, have been widely used for their treatment. Unfortunately, up to half of all ER α -positive tumors have intrinsic or acquired endocrine therapy resistance. Recent studies b…
  • College: College of Pharmacy
  • Inventors: Zhang, Xiaoting; Guo, Peixuan
  • Licensing Officer: Flammang, Ann Marie

Treatment of Multiple Sclerosis with small molecule IL-6/STAT3 inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: Flammang, Ann Marie

Phyllanthusmin and acutissimalignan A compound derivatives for anticancer and immunostimulation
TS-037721 — A group of potential antitumor arylnapthalene lactone derivatives, which may be developed as novel anticancer and immunostimulant agents.
Natural products and semi-synthetic derivatives derived from them have been used for anticancer drugs or drug leads for many years. However, side-effects such as myelosuppression and secondary leukemia have been reported. Furthermore, these natural products can be difficult to use for targeting sp…
  • College: College of Pharmacy
  • Inventors: Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Flammang, Ann Marie

STAT3 Inhibitors and Their Anti-Cancer Usage
TS-037671 — Novel non-peptidomimetic molecules for use as anti-cancer inhibitors of signal transducer and activator of transcription 3.
The search for more potent drug delivery candidates for cancer therapy remains a challenge within the medical community. Efforts to target cancer at the genetic level have led to numerous discoveries, including the role that constitutive activation of signal transducer and activator of transcripti…
  • College: College of Pharmacy
  • Inventors: Li, Chenglong; Lin, Jiayuh; Yu, Wenying
  • Licensing Officer: Flammang, Ann Marie

Effective Therapy of Hepatocellular Carcinoma with the Combination of Sorafenib and a Glucose Analog
TS-037248 — A novel therapeutic strategy to sensitize Hepatocellular Carcinoma tumors to a multikinase inhibitor for advanced stage treatment.
Hepatocellular carcinoma (HCC) kills nearly all patients within a year of diagnosis, and results in between 250,000 and one million deaths globally per year. In the US, incidences of HCC have nearly tripled in the past 30 years and currently remain one of the fastest growing causes of cancer-relat…
  • College: College of Medicine (COM)
  • Inventors: Motiwala, Tasneem; Jacob, Samson; Reyes, Ryan
  • Licensing Officer: Flammang, Ann Marie

Novel Use of Fostamatinib as a Therapeutic for Liver Cancer, both as First-Line Therapy and Following Acquired Resistance to Sorafenib
TS-032418 — A combination-therapy that has the potential to overcome and/or prevent the commonly observed acquisition of sorafenib resistance, which is associated with treatment failure in patients with hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) kills nearly all patients within a year of diagnosis, and results in between 250,000 and one million deaths globally per year. In the US, incidences of HCC have nearly tripled in the past 30 years and currently remain one of the fastest growing causes of cancer-relat…
  • College: College of Medicine (COM)
  • Inventors: Motiwala, Tasneem; Regan, Kelly; Reyes, Ryan
  • Licensing Officer: Flammang, Ann Marie

Anti-NCL Immunoagent for Cancer Diagnosis and Therapy
TS-015251 — Nucleolin (NCL) is up-regulated in cancer cells, and modulates pro-tumorigenic pathways and chemoresistance. This anti-NCL agent binds and blocks NCL signaling, and may be optimized as cancer therapeutic and diagnostic tool.
Despite huge advancements in detection and treatment, cancer remains a top world health concern. One of the major limitations of current technology is adequately detecting tumor margins and micrometastases. Even with aggressive tumor resection and adjuvant chemotherapy or radiotherapy, tumor cells…
  • College: College of Medicine (COM)
  • Inventors: Palmieri, Dario; Croce, Carlo; De Lorenzo, Claudia
  • Licensing Officer: Dahlman, Jason "Jay"

Self-Assembly of Therapeutic-Agent Nanostructures
TS-014812 — An improved delivery mechanism has been developed for hydrophobic drugs such as camptothecin which will increase chemotherapeutic efficacy.
Many cancer therapeutics exhibit extremely toxic side effects or have limited efficacy due to low bio-availability. Existing drug delivery technologies can add excessive mass to the therapeutic, grossly expanding the dosage necessary for response. Camptothecin (CPT) is a naturally occurring compou…
  • College: College of Arts & Sciences
  • Inventors: Parquette, Jonathan; Grinstaff, Mark; Kaplan, Jonah; Kim, Se Hye
  • Licensing Officer: Flammang, Ann Marie
PDF

Loading icon